人体类器官市场－全球产业规模、份额、趋势、机会与预测：按来源、器官类型、地区和竞争格局划分，2021-2031年

全球人类类器官市场预计将从 2025 年的 5.1224 亿美元成长到 2031 年的 6.5528 亿美元，复合年增长率为 4.19%。

这个产业的核心在于开发和商业化利用干细胞建构的三维体外组织模型，以模拟人体器官的结构和功能特征。推动这一增长的关键因素包括：迫切需要生理上精确的临床前模型来降低药物研发的高失败率；以及日益增长的伦理和监管压力，要求尽可能减少药物研究中对动物试验的依赖。与生物生物银行数位化等短期趋势不同，这些驱动因素旨在解决药物发现和个人化医疗中存在的根本性运作效率低下问题。

儘管存在这些成长要素，但缺乏标准化通讯协定和监管检验不足目前阻碍了行业层面的推广应用，并为许多机构设置了重大准入门槛。这种对采用替代检测方法的犹豫态度也反映在近期的产业数据中。根据皮斯托亚联盟（Pistoia Alliance）的调查，2024年接受调查的生命科学专业人士中，77%的人表示尚未将类器官等非动物模型整合到其研发流程中，主要原因是担心监管合规性和数据可重复性问题。

市场驱动因素

随着监管机构和製药公司致力于降低传统体内模型的高失败率，动物试验替代方案的出现正在从根本上改变市场结构。这项转变深受法规结构（例如FDA现代化法案2.0）的影响，该法案鼓励使用非动物替代方案来产生更具预测性的人体毒性数据。因此，安全药理学领域中动物试验的替代工具正在迅速商业化。例如，ATCC于2024年2月宣布的「ATCC-Tissue Dynamics伙伴关係」揭示了双方将共同开发一种与人体相关的类心臟器官试剂盒，旨在透过提供比动物模型更高的生理相关性来改善心臟安全性测试并降低药物研发风险。

再生医学领域研究经费和投资的激增进一步推动了市场扩张，为克服规模化和标准化障碍提供了必要的资金。领先的製药公司正积极透过高价值的合作研究，检验类器官技术在传统动物模型难以胜任的疾病领域的有效性。勃林格殷格翰与Ochre Bio的策略合作就是一个典型的例子。根据2024年4月发布的「勃林格殷格翰与Ochre Bio合作」新闻稿，该公司承诺投入高达10亿美元，利用先进的人类肝臟模型，探索治疗慢性肝病的新治疗方法。此外，为确保商业性可行性，工业化生产的资金也不断增加。例如，2024年4月Vertex与TreeFrog Therapeutics授权合约”，该协议价值高达7.8亿美元，旨在利用专有的C-Stem技术扩大细胞疗法的生产规模。

市场挑战

缺乏标准化通讯协定和监管检验不足，严重阻碍了全球人类类器官市场的产业化规模化发展。由于调查方法不一致导致数据输出存在差异，製药公司和研究机构仍犹豫是否将这些模型全面整合到关键决策流程中。当实验室工作流程在培养条件和表征指标方面存在显着差异时，最终数据缺乏监管申报所需的稳健性。因此，监管机构难以製定基于类器官的安全性和有效性评估的通用指南，迫使企业必须维持高成本的双重测试系统，其中包括传统的动物模型。

这种缺乏统一性直接阻碍了市场扩张，使类器官主要局限于探索性研究，而无法应用于检验的监管应用。近期产业调查结果凸显了这种操作上的碎片化程度。根据国际药物研发创新与品质联盟（IQ Consortium）2025年的调查，儘管76%的成员公司都在使用类器官等人源化肝臟模型，但该行业仍然面临「方法上的异质性」和不一致的风险评估策略。这种持续存在的差异削弱了这些模型作为体内试验唯一替代方案所需的可信度，从而阻碍了其更广泛的商业性应用。

市场趋势

将人工智慧 (AI) 和自动化技术融入培养流程，正迅速解决类器官培养的关键瓶颈问题，例如可重复性和劳动密集流程。为了管理成熟组织模型所需的复杂餵食和监测方案，实验室越来越多地采用机器学习驱动的机器人系统，从而最大限度地减少人为错误和变异性。近期的一些技术标竿也印证了这种操作方式的转变。根据 Molecular Devices 公司 2025 年 8 月发布的新闻稿，引入自动化振盪培养技术后，脑类器官培养板每週的人工操作量减少了高达 90%，实际工作时间从 27 小时缩短至仅几个小时。

同时，受託研究机构(CRO) 拓展高通量类器官筛检服务，正推动病患来源模型在大规模临床前试验的应用产业化。 CRO 透过整合大量特征明确的肿瘤样细胞库，为製药客户提供“体外临床试验”，从而在人体试验前快速筛选出有效患者。这种商业性能力的提昇在服务组合的成长中得到了清楚的体现。例如，根据 Crown Bioscience 2025 年 5 月发表的报导《利用类器官重新定义精准医疗》，该公司已建立了一个大型商业生物样本库，其中包含约 1000 个涵盖 22 种组织类型的类器官模型，以支持大规模药物和模型试验。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球人类类器官市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 供应来源（成体干细胞、诱导性多功能干细胞、胚胎干细胞、其他）
  • 依器官类型（胃模型、肠模型、肝臟模型、胰臟模型、肺部模型、脑部模型、肾臟模型、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美人类类器官市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲人类类器官市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区人类类器官市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲人类类器官市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲人类类器官市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球人类类器官市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• American Type Culture Collection（ATCC）
• Thermo Fisher Scientific Inc.
• STEMCELL Technologies Canada Inc.
• Merck KGaA
• Corning Incorporated
• Bio-Techne Corporation
• ACROBIOSYSTEMS INC.
• AMS Biotechnology（Europe）Ltd
• Qkine Ltd.
• PRIMACYT Cell Culture Technology GmbH

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Human Organoids Market is projected to expand from a valuation of USD 512.24 Million in 2025 to USD 655.28 Million by 2031, reflecting a CAGR of 4.19%. This industry centers on the creation and commercialization of three-dimensional in vitro tissue models engineered from stem cells to mimic the structural and functional properties of human organs. The primary drivers of this growth include the urgent need for physiologically accurate preclinical models to lower high drug failure rates, alongside intensifying ethical and regulatory pressure to minimize reliance on animal testing in pharmaceutical research. Unlike temporary trends such as the digitization of bio-banking, these drivers address fundamental operational inefficiencies within drug discovery and personalized medicine.

Despite these growth factors, widespread industrial adoption is currently hindered by the lack of standardized protocols and regulatory validation, creating significant barriers to entry for many organizations. This hesitation to adopt alternative testing methods is reflected in recent industry data. According to the Pistoia Alliance, in 2024, 77% of surveyed life sciences professionals indicated they were not yet integrating non-animal models, such as organoids, into their research and development workflows, largely citing concerns regarding regulatory compliance and data reproducibility.

Market Driver

The shift toward alternatives to animal testing is fundamentally reshaping the market as regulatory bodies and pharmaceutical companies strive to reduce the high attrition rates associated with traditional in vivo models. This transition is heavily influenced by the implementation of regulatory frameworks like the FDA Modernization Act 2.0, which promotes the use of non-animal alternatives for generating more predictive human toxicity data. Consequently, the industry is seeing rapid commercialization of tools designed to replace animal testing in safety pharmacology. For example, according to ATCC in February 2024, the 'ATCC and Tissue Dynamics Partnership' was announced to collaboratively develop human-relevant cardiac organoid kits aimed at improving cardiac safety testing and mitigating drug development risks by offering higher physiological relevance than animal models.

Market expansion is further supported by a surge in research funding and investments in regenerative medicine, providing the capital necessary to overcome scalability and standardization hurdles. Major pharmaceutical companies are actively validating organoid technology through high-value collaborations in disease areas where animal models have historically failed. A key example is the strategic deal between Boehringer Ingelheim and Ochre Bio; as per the April 2024 'Boehringer Ingelheim and Ochre Bio Partnership' press release, the company committed up to $1 billion in potential payments to discover novel treatments for chronic liver diseases using advanced human liver models. Additionally, capital is increasingly targeting industrial manufacturing to ensure commercial viability, as highlighted by the April 2024 'Vertex and TreeFrog Therapeutics License Agreement,' where a collaboration valued at up to $780 million was established to scale cell therapy manufacturing using proprietary C-Stem technology.

Market Challenge

The absence of standardized protocols and regulatory validation represents a significant barrier to the industrial scalability of the Global Human Organoids Market. Pharmaceutical companies and research organizations remain hesitant to fully integrate these models into critical decision-making processes because inconsistent methodologies result in variable data outputs. When laboratory workflows differ substantially in culture conditions and characterization metrics, the resulting data lacks the robustness required for regulatory submissions. Consequently, regulatory bodies struggle to establish universal guidelines for organoid-based safety and efficacy assessments, compelling companies to maintain expensive dual testing streams that include traditional animal models.

This lack of uniformity directly restricts market expansion by limiting organoids primarily to exploratory research rather than validated regulatory applications. The extent of this operational fragmentation is underscored by recent industry findings. According to a 2025 survey by the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium), although 76% of member companies utilized humanized liver models such as organoids, the industry continues to grapple with "heterogeneity in approaches" and a lack of consistent risk assessment strategies. This persistent variability undermines the confidence required for these models to function as standalone replacements for in vivo testing, thereby stalling their broader commercial adoption.

Market Trends

The integration of artificial intelligence and automation into culture processes is rapidly addressing the critical bottlenecks of reproducibility and labor intensity in organoid maintenance. Laboratories are increasingly utilizing machine learning-driven robotic systems to manage the complex feeding and monitoring schedules necessary for mature tissue models, thereby minimizing human error and variability. This operational shift is demonstrated by recent technological benchmarks; according to a Molecular Devices press release in August 2025, the integration of automated rocking incubation reduced the weekly manual labor for maintaining brain organoid plates by up to 90%, cutting hands-on time from 27 hours to just a few hours.

Simultaneously, the expansion of high-throughput organoid screening services by Contract Research Organizations (CROs) is industrializing the use of patient-derived models for large-scale preclinical trials. CROs are aggregating extensive libraries of well-characterized tumoroids to offer pharmaceutical clients "clinical trials in a dish," enabling the rapid stratification of patient responders prior to human testing. This scaling of commercial capabilities is evident in the growth of service portfolios; for instance, according to Crown Bioscience's May 2025 article 'Redefining Precision Medicine with Organoids,' the company has established a massive commercial biobank containing nearly 1,000 organoid models across 22 different tissue types to support large-scale drug and model testing.

Key Market Players

• American Type Culture Collection (ATCC)
• Thermo Fisher Scientific Inc.
• STEMCELL Technologies Canada Inc.
• Merck KGaA
• Corning Incorporated
• Bio-Techne Corporation
• ACROBIOSYSTEMS INC.
• AMS Biotechnology (Europe) Ltd
• Qkine Ltd.
• PRIMACYT Cell Culture Technology GmbH

Report Scope

In this report, the Global Human Organoids Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Organoids Market, By Source

• Adult Stem Cells
• Induced Pluripotent Stem Cells
• Embryonic Stem Cells
• Others

Human Organoids Market, By Organ Type

• Stomach Models
• Intestine Models
• Liver Models
• Pancreatic Models
• Lung Models
• Brain Models
• Kidney Models
• Others

Human Organoids Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Organoids Market.

Available Customizations:

Global Human Organoids Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Organoids Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, Others)
  • 5.2.2. By Organ Type (Stomach Models, Intestine Models, Liver Models, Pancreatic Models, Lung Models, Brain Models, Kidney Models, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Human Organoids Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Organ Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Organoids Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Organ Type
  • 6.3.2. Canada Human Organoids Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Organ Type
  • 6.3.3. Mexico Human Organoids Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Organ Type

7. Europe Human Organoids Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Organ Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Organoids Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Organ Type
  • 7.3.2. France Human Organoids Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Organ Type
  • 7.3.3. United Kingdom Human Organoids Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Organ Type
  • 7.3.4. Italy Human Organoids Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Organ Type
  • 7.3.5. Spain Human Organoids Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Organ Type

8. Asia Pacific Human Organoids Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Organ Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Human Organoids Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Organ Type
  • 8.3.2. India Human Organoids Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Organ Type
  • 8.3.3. Japan Human Organoids Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Organ Type
  • 8.3.4. South Korea Human Organoids Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Organ Type
  • 8.3.5. Australia Human Organoids Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Organ Type

9. Middle East & Africa Human Organoids Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Organ Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Human Organoids Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Organ Type
  • 9.3.2. UAE Human Organoids Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Organ Type
  • 9.3.3. South Africa Human Organoids Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Organ Type

10. South America Human Organoids Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Organ Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Human Organoids Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Organ Type
  • 10.3.2. Colombia Human Organoids Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Organ Type
  • 10.3.3. Argentina Human Organoids Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Organ Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Human Organoids Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. American Type Culture Collection (ATCC)
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. STEMCELL Technologies Canada Inc.
• 15.4. Merck KGaA
• 15.5. Corning Incorporated
• 15.6. Bio-Techne Corporation
• 15.7. ACROBIOSYSTEMS INC.
• 15.8. AMS Biotechnology (Europe) Ltd
• 15.9. Qkine Ltd.
• 15.10. PRIMACYT Cell Culture Technology GmbH

16. Strategic Recommendations

17. About Us & Disclaimer